Back to Selank research
selank anxiolytic preclinical animal n preclinical 2026-04-03 PubMed

Selank Restores Cognitive Function After Early Brain Damage in Rats

Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny.

Background

The cerebral catecholamine system, a network of neurons crucial for regulating mood, attention, and cognitive function, can be severely damaged during early ontogeny (early development). Such damage, often caused by neurotoxins, leads to persistent cognitive impairments affecting learning, memory, and attention throughout life. This study specifically addresses the knowledge gap of whether the synthetic peptide Selank can effectively restore these disordered cognitive processes following early-life damage to the catecholamine system.

Results

The study found that Selank treatment profoundly improved cognitive functions in the rats with early-life brain damage. Specifically, administration of Selank at 0.3 mg/kg led to a significant restoration of learning abilities, memory retention, and attention to various sensory stimuli. The cognitive performance of the Selank-treated rats was notably enhanced compared to untreated controls, demonstrating a robust therapeutic effect. These improvements were observed across multiple cognitive domains, suggesting a broad impact on brain function. The most important finding was that Selank effectively normalized cognitive processes that were severely impaired by chronic artificial inhibition of the cerebral catecholaminergic system during early development.

Why It Matters

This research highlights the significant potential of Selank as a therapeutic agent for cognitive impairments resulting from early-life neurological damage. The ability of Selank to restore complex cognitive functions after substantial brain insult is a crucial finding, offering hope for conditions with similar etiologies. This suggests Selank could be a promising candidate for treating cognitive deficits in humans resulting from early brain injury, neurodevelopmental disorders, or other conditions affecting the catecholamine system. Future research should focus on elucidating the precise molecular mechanisms of action and conducting further preclinical studies to pave the way for human clinical trials and potential clinical use.


selank anxiolytic nootropic dose mentioned
Source: pubmed:18683497 · Ingested 2026-04-03 · Digest: gemini-2.5-flash